Yoon Tae Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoon Tae Kim has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Aaron L. Sarver
University of Minnesota
2 shared publications - Ashley J. Schulte
Animal Cancer Care and Research Program, University of Minnesota, St Paul, Minnesota; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
2 shared publications - Cheolju Lee
Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea
2 shared publications - Colleen L. Forster
The University of Minnesota Biological Materials Procurement Network (BioNet), University of Minnesota, Minneapolis, Minnesota
2 shared publications - Elinor K. Karlsson
Broad Institute of MIT and Harvard, Cambridge, MA, USA
2 shared publications Eunho Chun
Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 5 February 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (3) , 665
Author Correction: Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
- 5 February 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (3) , 665
Open AccessAuthor Correction: Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
- Open Access
- 14 December 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (1) , 40-63
Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
Despite intensive clinical and scientific efforts, the mortality rate of sepsis remains high due to the lack of precise biomarkers for patient stratification and therapeutic guidance. Secreted human tryptophanyl-tRNA synthetase 1 (WARS1), an endogenous ligand for Toll-like receptor (TLR) 2 and TLR4 against infection, activates the genes that signify the hyperinflammatory sepsis phenotype. High plasma WARS1 levels stratified the early death of critically ill patients with sepsis, along with elevated levels of cytokines, chemokines, and lactate, as well as increased numbers of absolute neutrophils and monocytes, and higher Sequential Organ Failure Assessment (SOFA) scores. These symptoms were recapitulated in severely ill septic mice with hypercytokinemia. Further, injection of WARS1 into mildly septic mice worsened morbidity and mortality. We created an anti-human WARS1-neutralizing antibody that suppresses proinflammatory cytokine expression in marmosets with endotoxemia. Administration of this antibody into severe septic mice attenuated cytokine storm, organ failure, and early mortality. With antibiotics, the antibody almost completely prevented fatalities. These data imply that blood-circulating WARS1-guided anti-WARS1 therapy may provide a novel theranostic strategy for life-threatening systemic hyperinflammatory sepsis.
- 14 December 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (1) , 40-63
Open AccessHighly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
Despite intensive clinical and scientific efforts, the mortality rate of sepsis remains high due to the lack of precise biomarkers for patient stratification and therapeutic guidance. Secreted human tryptophanyl-tRNA synthetase 1 (WARS1), an endogenous ligand for Toll-like receptor (TLR) 2 and TLR4 against infection, activates the genes that signify the hyperinflammatory sepsis phenotype. High plasma WARS1 levels stratified the early death of critically ill patients with sepsis, along with elevated levels of cytokines, chemokines, and lactate, as well as increased numbers of absolute neutrophils and monocytes, and higher Sequential Organ Failure Assessment (SOFA) scores. These symptoms were recapitulated in severely ill septic mice with hypercytokinemia. Further, injection of WARS1 into mildly septic mice worsened morbidity and mortality. We created an anti-human WARS1-neutralizing antibody that suppresses proinflammatory cytokine expression in marmosets with endotoxemia. Administration of this antibody into severe septic mice attenuated cytokine storm, organ failure, and early mortality. With antibiotics, the antibody almost completely prevented fatalities. These data imply that blood-circulating WARS1-guided anti-WARS1 therapy may provide a novel theranostic strategy for life-threatening systemic hyperinflammatory sepsis.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-15 from Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions
Table S1. Demographic and pathological features of human patients with angiosarcoma Table S2. Demographic and pathological features of dogs with HSA Table S3. Primary antibodies for immunohistochemical evaluation Table S4. Gene ontology and biological functions of fusion partner genes in human angiosarcomas Table S5. Gene ontology and biological functions of fusion partner genes in canine HSAs Table S6. Detection of fusion genes in canine HSAs by RT-PCR Table S7. Biological functions associated with 490 upregulated genes in human angiosarcomas Table S8. Association of frequency between fusion genes, TP53 and PIK3CA mutations Table S9. Association of fusion genes with dog signalment and tumor histology Table S10. Association of frequency between fusion genes, TP53 and PIK3CA mutations Table S11. 41 differentially expressed genes in PF (n = 4) compared to P (n = 9) group Table S12. 212 differentially expressed genes in PF (n = 4) compared to PK (n = 6) group Table S13. 377 differentially expressed genes in PF (n = 4) compared to PFK (n = 4) group Table S14. Immunohistochemical features of human angiosarcomas Table S15. Immunohistochemical features of canine HSAs
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-15 from Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions
Table S1. Demographic and pathological features of human patients with angiosarcoma Table S2. Demographic and pathological features of dogs with HSA Table S3. Primary antibodies for immunohistochemical evaluation Table S4. Gene ontology and biological functions of fusion partner genes in human angiosarcomas Table S5. Gene ontology and biological functions of fusion partner genes in canine HSAs Table S6. Detection of fusion genes in canine HSAs by RT-PCR Table S7. Biological functions associated with 490 upregulated genes in human angiosarcomas Table S8. Association of frequency between fusion genes, TP53 and PIK3CA mutations Table S9. Association of fusion genes with dog signalment and tumor histology Table S10. Association of frequency between fusion genes, TP53 and PIK3CA mutations Table S11. 41 differentially expressed genes in PF (n = 4) compared to P (n = 9) group Table S12. 212 differentially expressed genes in PF (n = 4) compared to PK (n = 6) group Table S13. 377 differentially expressed genes in PF (n = 4) compared to PFK (n = 4) group Table S14. Immunohistochemical features of human angiosarcomas Table S15. Immunohistochemical features of canine HSAs
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-12 from Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions
S1. Representative putative inter-chromosomal fusion transcripts in human AS and canine HSA. SCLT1-NIPBL fusion in human angiosarcoma. S2. Fusion genes and their association with tumor content and sequencing depth in canine HSA tissues. S3. A, Primers designed for amplification of SCLT1-NIPBL fusion transcripts identified in human angiosarcoma. B, SCLT1-NIPBL fusion gene amplification by quantitative RT-PCR. Expression value represents 2(-â^†Ct)(Fusion gene/GAPDH). C, Primers designed for amplification of four fusion transcripts identified in canine hemangiosarcomas. D, Fusion gene amplification was confirmed in canine tumors by quantitative RT-PCR. E, Electrophoresis (1% agarose gel) of DNA product by RTPCR was done. S4. Genetic alterations of fusion partner genes identified in human AS. S5. Cell type enrichment analysis in ASs and TCGA sarcomas. S6. Three distinct molecular groups of canine HSAs. S7. Kaplan-Meier probability of survival for dogs with angiogenic and inflammatory HSA. S8. Association of the fusion events with demographic and histopathologic features in canine HSA. S9. Gene pathways associated with commonly enriched genes in tumors with fusion genes and TP53 mutations in canine HSA. S10. Violin plots display IHC scores of p53, p-p53 (Ser15), and p-p53 (Ser20) in human AS and canine HSA. S11. Violin plots present IHC scores of AKT and p-AKT (Thr308) in human AS and canine HSA. S12. IHC scores of mTOR and p-mTOR (Ser2448) in human AS.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-12 from Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions
S1. Representative putative inter-chromosomal fusion transcripts in human AS and canine HSA. SCLT1-NIPBL fusion in human angiosarcoma. S2. Fusion genes and their association with tumor content and sequencing depth in canine HSA tissues. S3. A, Primers designed for amplification of SCLT1-NIPBL fusion transcripts identified in human angiosarcoma. B, SCLT1-NIPBL fusion gene amplification by quantitative RT-PCR. Expression value represents 2(-â^†Ct)(Fusion gene/GAPDH). C, Primers designed for amplification of four fusion transcripts identified in canine hemangiosarcomas. D, Fusion gene amplification was confirmed in canine tumors by quantitative RT-PCR. E, Electrophoresis (1% agarose gel) of DNA product by RTPCR was done. S4. Genetic alterations of fusion partner genes identified in human AS. S5. Cell type enrichment analysis in ASs and TCGA sarcomas. S6. Three distinct molecular groups of canine HSAs. S7. Kaplan-Meier probability of survival for dogs with angiogenic and inflammatory HSA. S8. Association of the fusion events with demographic and histopathologic features in canine HSA. S9. Gene pathways associated with commonly enriched genes in tumors with fusion genes and TP53 mutations in canine HSA. S10. Violin plots display IHC scores of p53, p-p53 (Ser15), and p-p53 (Ser20) in human AS and canine HSA. S11. Violin plots present IHC scores of AKT and p-AKT (Thr308) in human AS and canine HSA. S12. IHC scores of mTOR and p-mTOR (Ser2448) in human AS.